Anti-Angiogenic Activity Of Bevacizumab-Bearing Dexamethasone-Loaded PLGA Nanoparticles For Potential Intravitreal Applications

References

• Zhao M, Mantel I, Gelize E, et al. Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration. Nat Commun. 2019;10:1–13. doi:10.1038/S41467-018-08125-6
   Web of Science ®Google Scholar
• Mu H, Wang Y, Chu Y, et al. Multivesicular liposomes for sustained release of bevacizumab in treating laser-induced choroidal neovascularization. Drug Deliv. 2018;25(1):1372–1383. doi:10.1080/10717544.2018.147496729869520
   PubMed Web of Science ®Google Scholar
• Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol. 2003;48(3):257–293. doi:10.1016/S0039-6257(03)00030-412745003
   PubMed Web of Science ®Google Scholar
• Iyer S, Radwan AE, Hafezi-Moghadam A, Malyala P, Amiji M. Long-acting intraocular delivery strategies for biological therapy of age-related macular degeneration. J Control Release. 2019;296:140–149. doi:10.1016/j.jconrel.2019.01.00730660630
   PubMedGoogle Scholar
• Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171–185. doi:10.1007/s10456-011-9249-622302382
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432–1444. doi:10.1056/NEJMoa06265517021319
   PubMed Web of Science ®Google Scholar
• Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002;120(3):338–346. doi:10.1001/archopht.120.3.33811879138
   PubMed Web of Science ®Google Scholar
• Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005;112(6):1035–1047.e1039. doi:10.1016/j.ophtha.2005.02.00715936441
   PubMed Web of Science ®Google Scholar
• Hoffart L, Matonti F, Conrath J, et al. Inhibition of corneal neovascularization after alkali burn: comparison of different doses of bevacizumab in monotherapy or associated with dexamethasone. Clin Experiment Ophthalmol. 2010;38(4):346–352. doi:10.1111/ceo.2010.38.issue-421077280
   PubMed Web of Science ®Google Scholar
• Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol. 1998;341(2–3):309–315. doi:10.1016/S0014-2999(97)01464-79543253
   PubMed Web of Science ®Google Scholar
• Hiroshi T, Kazuaki M, Junichi K, et al. Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci. 2005;46(4):1440–1444.
   Google Scholar
• Zhang L, Chan JM, Gu FX, et al. Self-assembled lipid–polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano. 2008;2(8):1696–1702. doi:10.1021/nn800275r19206374
   PubMed Web of Science ®Google Scholar
• Xie J, Yang Z, Zhou C, Zhu J, Lee RJ, Teng LJBA. Nanotechnology for the delivery of phytochemicals in cancer therapy. Biotech Adv. 2016;34(4):343–353.
   Google Scholar
• Garg NK, Singh B, Sharma G, et al. Development and characterization of single step self-assembled lipid polymer hybrid nanoparticles for effective delivery of methotrexate. RSC Adv. 2015;5(77):62989–62999. doi:10.1039/C5RA12459J
   Web of Science ®Google Scholar
• Gomez-Graete C, Tsapis N, Besnard M, Bochot A, Fattal E. Encapsulation of dexamethasone into biodegradable polymeric nanoparticles. Int J Pharm. 2007;331(2):153–159. doi:10.1016/j.ijpharm.2006.11.02817157461
   PubMedGoogle Scholar
• Barcia E, Herrero-Vanrell R, Diez A, Alvarez-Santiago C, Lopez I, Calonge M. Downregulation of endotoxin-induced uveitis by intravitreal injection of polylactic-glycolic acid (PLGA) microspheres loaded with dexamethasone. Exp Eye Res. 2009;89(2):238–245. doi:10.1016/j.exer.2009.03.01219341729
   PubMed Web of Science ®Google Scholar
• Xu J, Wang Y, Li Y, et al. Inhibitory efficacy of intravitreal dexamethasone acetate-loaded PLGA nanoparticles on choroidal neovascularization in a laser-induced rat model. J Ocul Pharmacol Ther. 2007;23(6):527–539. doi:10.1089/jop.2007.000218001232
   PubMed Web of Science ®Google Scholar
• Shen J, Durairaj C, Lin T, Liu Y, Burke J. Ocular pharmacokinetics of intravitreally administered brimonidine and dexamethasone in animal models with and without blood-retinal barrier breakdown. Invest Ophthalmol Vis Sci. 2014;55(2):1056–1066. doi:10.1167/iovs.13-1365024448267
   PubMedGoogle Scholar
• Kassumeh SA, Wertheimer CM, von Studnitz A, et al. Poly(lactic-co-glycolic) acid as a slow-release drug-carrying matrix for methotrexate coated onto intraocular lenses to conquer posterior capsule opacification. Curr Eye Res. 2018;43(6):702–708. doi:10.1080/02713683.2018.143745529451997
   PubMed Web of Science ®Google Scholar
• Nimesh S. 10 - Polyethylenimine nanoparticles In: Nimesh S, editor. Gene Therapy. Woodhead Publishing; 2013:197–223.
   Google Scholar
• Olbrich C, Bakowsky U, Lehr C-M, Müller RH, Kneuer C. Cationic solid-lipid nanoparticles can efficiently bind and transfect plasmid DNA. J Control Release. 2001;77(3):345–355. doi:10.1016/S0168-3659(01)00506-511733101
   PubMedGoogle Scholar
• Yu K, Zhao J, Zhang Z, et al. Enhanced delivery of Paclitaxel using electrostatically-conjugated Herceptin-bearing PEI/PLGA nanoparticles against HER-positive breast cancer cells. Int J Pharm. 2016;497(1–2):78–87. doi:10.1016/j.ijpharm.2015.11.03326617314
   PubMed Web of Science ®Google Scholar
• Terelak-Borys B, Zagajewska K, Jankowska-Lech I, Tesla P, Grabska-Liberek I. Combined treatment in punctate inner choroidopathy. Ther Clin Risk Manag. 2016;12:1467–1471. doi:10.2147/TCRM.S11055627729795
   PubMed Web of Science ®Google Scholar
• Fornaguera C, Dols-Perez A, Caldero G, Garcia-Celma MJ, Camarasa J, Solans C. PLGA nanoparticles prepared by nano-emulsion templating using low-energy methods as efficient nanocarriers for drug delivery across the blood-brain barrier. J Control Release. 2015;211:134–143. doi:10.1016/j.jconrel.2015.06.00226057857
   PubMed Web of Science ®Google Scholar
• Liu J, Li S, Li G, et al. Highly bioactive, bevacizumab-loaded, sustained-release PLGA/PCADK microspheres for intravitreal therapy in ocular diseases. Int J Pharm. 2019;563:228–236. doi:10.1016/j.ijpharm.2019.04.01230959236
   PubMedGoogle Scholar
• Gong C, Deng S, Wu Q, et al. Improving antiangiogenesis and anti-tumor activity of curcumin by biodegradable polymeric micelles. Biomaterials. 2013;34(4):1413–1432. doi:10.1016/j.biomaterials.2012.10.06823164423
   PubMed Web of Science ®Google Scholar
• Qi X, Cai J, Ruan Q, et al. γ-Secretase inhibition of murine choroidal neovascularization is associated with reduction of superoxide and proinflammatory cytokines. Invest Ophthalmol Vis Sci. 2012;53(2):574–585.
   Google Scholar
• Liu L, Qi X, Chen Z, et al. Targeting the IRE1α/XBP1 and ATF6 arms of the unfolded protein response enhances VEGF blockade to prevent retinal and choroidal neovascularization. Am J Pathol. 2013;182(4):1412–1424. doi:10.1016/j.ajpath.2012.12.02023395094
   PubMed Web of Science ®Google Scholar
• Bishop PN. Structural macromolecules and supramolecular organisation of the vitreous gel. Prog Retin Eye Res. 2000;19(3):323–344. doi:10.1016/S1350-9462(99)00016-610749380
   PubMed Web of Science ®Google Scholar
• Chan LW, Camphausen K. Angiogenic tumor markers, antiangiogenic agents and radiation therapy. Expert Rev Anticancer Ther. 2003;3(3):357–366. doi:10.1586/14737140.3.3.35712820778
   PubMedGoogle Scholar
• Li ML, Ping G, Plathow C, et al. Small molecule receptor tyrosine kinase inhibitor of platelet-derived growth factor signaling (SU9518) modifies radiation response in fibroblasts and endothelial cells. BMC Cancer. 2006;6. doi:10.1186/1471-2407-6-79
   Web of Science ®Google Scholar
• Sakurai E, Ozeki H, Kunou N, Ogura YJOR. Effect of particle size of polymeric nanospheres on intravitreal kinetics. Ophthalmic Res. 2001;33(1):31–36. doi:10.1159/00005563811114602
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhang X, Sun X, et al. Dual-functional lipid polymeric hybrid pH-responsive nanoparticles decorated with cell penetrating peptide and folate for therapy against rheumatoid arthritis. Eur J Pharm Biopharm. 2018;130:39–47. doi:10.1016/j.ejpb.2018.06.02029928978
   PubMed Web of Science ®Google Scholar
• Zakarija A, Soff G. Update on angiogenesis inhibitors. Curr Opin Oncol. 2005;17(6):578–583. doi:10.1097/01.cco.0000183672.15133.ab16224236
   PubMedGoogle Scholar
• Wu Y, Zhong Z, Huber J, et al. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer. Clin Cancer Res. 2006;12(21):6573–6584. doi:10.1158/1078-0432.CCR-06-083117085673
   PubMed Web of Science ®Google Scholar
• Voravud N, Charuruk N. Tumor angiogenesis. J Med Associat Thai. 1999;82(4):394.
   Google Scholar